Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Fish and Richardson
Johnson and Johnson
Mallinckrodt
Colorcon
Accenture
Julphar
Argus Health
Chubb
Harvard Business School

Generated: August 19, 2017

DrugPatentWatch Database Preview

Takeda Company Profile

« Back to Dashboard

What is the competitive landscape for TAKEDA, and when can generic versions of TAKEDA drugs launch?

TAKEDA has twenty-four approved drugs.

There are ninety-two US patents protecting TAKEDA drugs and there have been two Paragraph IV challenges on TAKEDA drugs in the past three years.

There are one thousand two hundred and eighty-eight patent family members on TAKEDA drugs in sixty-six countries.

Summary for Applicant: Takeda

Patents:92
Tradenames:25
Ingredients:17
NDAs:24
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-002Jan 25, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
Takeda Pharms Usa
DEXILANT SOLUTAB
dexlansoprazole
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL208056-001Jan 26, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-002Mar 27, 2012DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-004Mar 27, 2012DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-001Mar 27, 2012DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Takeda

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Takeda Gmbh
ALVESCO
ciclesonide
AEROSOL, METERED;INHALATION021658-002Jan 10, 2008► Subscribe► Subscribe
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-002Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-001Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms Na
PREVACID
lansoprazole
FOR SUSPENSION, DELAYED RELEASE;ORAL021281-002May 3, 2001► Subscribe► Subscribe
Takeda Pharms Usa
ACTOS
pioglitazone hydrochloride
TABLET;ORAL021073-001Jul 15, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for TAKEDA drugs

Drugname Dosage Strength Tradename Submissiondate
alogliptin
Tablets6.25 mg, 12.5 mg and 25 mg
NESINA
1/25/2017
alogliptin and metformin hydrochloride
Tablets12.5 mg/500 mg and 12.5 mg/1000 mg
KAZANO
1/25/2017
febuxostat
Tablets40 mg and 80 mg
ULORIC
2/13/2013
ciclesonide
Nasal Spray250 mcg
OMNARIS
2/13/2012
colchicine
Tablets0.6 mg
COLCRYS
12/23/2011
pioglitazone hydrochloride and metformin hydrochloride
Extended-release Tablets15 mg/1000 mg and 30 mg/1000 mg
ACTOPLUS MET XR
9/23/2011
dexlansoprazole
Delayed-release Capsule30 mg
DEXILANT
11/30/2010
dexlansoprazole
Capsule60 mg
DEXILANT
8/25/2010
pioglitazone hydrochloride and glimepiride
Tablets30 mg/2 mg and 30 mg/4 mg
DUETACT
12/22/2009
ramelteon
Tablets8 mg
ROZEREM
7/22/2009
pioglitazone hydrochloride and metformin hydrochloride
Tablets15 mg/500 mg and 15 mg/850 mg
ACTOPLUS MET
3/6/2008
lansoprazole
Delayed-release Orally Disinte15 mg and 30 mg
PREVACID
12/27/2006
lansoprazole
Delayed-release Pellets/Capsul15 mg and 30 mg
PREVACID
12/5/2005

Non-Orange Book Patents for Takeda

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,218,409 Pharmaceutical composition► Subscribe
6,080,765 Pharmaceutical composition► Subscribe
6,274,605 Pharmaceutical composition► Subscribe
8,304,391Peptides that bind to the erythropoietin receptor► Subscribe
8,110,567Phenyl-piperazine derivatives as serotonin reuptake inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Takeda Drugs

Country Document Number Estimated Expiration
Taiwan585786► Subscribe
Cyprus1108393► Subscribe
World Intellectual Property Organization (WIPO)2006106815► Subscribe
Portugal1337525► Subscribe
Germany69941115► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Takeda Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0033France► SubscribePRODUCT NAME: VORTIOXETINE OU L'UN DE SES SELS D'ADDITION D'ACIDE PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/891 20131218
2014000049Germany► SubscribePRODUCT NAME: VORTIOXETIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SAEUREADDITIONSSALZ DAVON; REGISTRATION NO/DATE: EU/1/13/891 20131218
00707Netherlands► SubscribePRODUCT NAME: SAXAGLIPTIN; REGISTRATION NO/DATE: EU/1/09/545/001-010 20091001
2 5006-2014Slovakia► SubscribePRODUCT NAME: ALOGLIPTIN VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/13/844/001 - EU/1/13/844/027 20130923
2014 00063Denmark► SubscribePRODUCT NAME: SITAGLIPTIN OG FARMACEUTISK SALTE DERAF, HERUNDER SITAGLIPTIN PHOSPHAT MONOHYDRAT; REG. NO/DATE: EU/1/07/383/001-024 AND EU/1/07/382/001-024 20070321
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Chinese Patent Office
Fuji
Mallinckrodt
Chubb
US Army
Express Scripts
McKesson
UBS
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot